Use of the complement inhibitor Coversin to treat HSCT-associated TMA

Abstract excerpt

Finding an inherited complement abnormality in HSCT-associated TMA provides a rationale for the use of a complement inhibitor.Alternative complement inhibitors such as Coversin should be considered in patients who are resistant to eculizumab.

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Blood groups and transfusion
• Share to Complement system in diseases
• Share to Renal Diseases and Glomerulopathies